TANDem-2: Closing the Gap to Interventions for TAND
Launched by VRIJE UNIVERSITEIT BRUSSEL · Mar 13, 2025
Trial Information
Current as of April 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The investigators hypothesize that an innovative, ultra-brief caregiver wellbeing intervention developed for caregivers of children with developmental disabilities can be adapted as a universal caregiver wellbeing intervention in tuberous sclerosis complex (TSC), that it can be delivered feasibly in an online modality, and will result in changes in key caregiver wellbeing factors. To test these hypotheses, the researchers will adapt the 3-session 'Well-Beans for Caregivers' program through a participatory method with the TAND consortium (the TAND consortium is an international group of clin...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult caregiver of an individual with Tuberous Sclerosis Complex (TSC) of any age
- Exclusion Criteria:
- • Not an adult caregiver of an individual with TSC
Trial Officials
Anna Jansen, MD, PhD
Principal Investigator
Vrije Universiteit Brussel
Petrus J de Vries, MD PhD
Principal Investigator
University of Cape Town
About Vrije Universiteit Brussel
The Vrije Universiteit Brussel (VUB) is a distinguished research university located in Brussels, Belgium, known for its commitment to innovative education and cutting-edge research across various disciplines. As a clinical trial sponsor, VUB actively engages in advancing medical knowledge and improving patient care through rigorous scientific investigations. The university fosters collaborations with healthcare institutions and industry partners, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements. VUB's research initiatives are driven by a multidisciplinary approach, leveraging expertise from fields such as medicine, health sciences, and biomedical engineering to address pressing health challenges and contribute to the development of novel therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported